CHAPTER 16 – Clinical Applications of Tumor-Suppressor Gene Therapy
作者： RAYMOND D. MENG , WAFIK S. EL-DEIRY
DOI: 10.1016/B978-012437551-2/50017-3
关键词:
摘要: Clinical Applications of Tumor-Suppressor Gene Therapy The application tumor suppressors in gene therapy represents an important strategy the war against cancer. Multiple human tumors show mutations or deletions suppressor genes, which control cellular growth by regulating cell cycle inducing apoptosis. One cancer has focused on replacement overexpression genes. p53 remains most being developed and its combination with chemotherapy radiotherapy may prove to be even more beneficial. Currently, only progressed clinical trials. However, not represent ideal choice for all cancers. In cells that overexpress MDM2 have HPV 16 E6, other such as p21 desirable targets because they can bypass inactivation p53. addition p21, been studied include p16, Rb, p27, p14, PTEN, BRCA1, VHL, FHIT.
sci-hub.st 参考文章(28)
Carla Heise, Terry Hermiston, Leisa Johnson, Gabriel Brooks, Adam Sampson-Johannes, Angelica Williams, Lyndah Hawkins, David Kirn, An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy Nature Medicine. ,vol. 6, pp. 1134- 1139 ,(2000) , 10.1038/80474
Felicia D. Goodrum, David A. Ornelles, p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection Journal of Virology. ,vol. 72, pp. 9479- 9490 ,(1998) , 10.1128/JVI.72.12.9479-9490.1998
David M. Jablons, Liang You, Cheng-Ta Yang, ONYX-015 Works Synergistically with Chemotherapy in Lung Cancer Cell Lines and Primary Cultures Freshly Made from Lung Cancer Patients Cancer Research. ,vol. 60, pp. 1009- 1013 ,(2000)
Fadlo R. Khuri, John Nemunaitis, Ian Ganly, James Arseneau, Ian F. Tannock, Larry Romel, Martin Gore, Janet Ironside, R.H. MacDougall, Carla Heise, Britta Randlev, Ann M. Gillenwater, Patricia Bruso, Stanley B. Kaye, Waun Ki Hong, David H. Kirn, A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Medicine. ,vol. 6, pp. 879- 885 ,(2000) , 10.1038/78638
Sheryl Redlin-Frazier, Patrice S. Obermiller, Jeffrey T. Holt, Allison R. Hatmaker, David L. Tait, Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. Clinical Cancer Research. ,vol. 5, pp. 1708- 1714 ,(1999)
Svend O. Freytag, Kenneth R. Rogulski, Dell L. Paielli, David H. Kirn, Carla C. Heise, Jeff D. Gilbert, Kang Zhang, Jae Ho Kim, In Vivo Antitumor Activity of ONYX-015 Is Influenced by p53 Status and Is Augmented by Radiotherapy Cancer Research. ,vol. 60, pp. 1193- 1196 ,(2000)
Josephine N. Harada, Arnold J. Berk, p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication Journal of Virology. ,vol. 73, pp. 5333- 5344 ,(1999) , 10.1128/JVI.73.7.5333-5344.1999
Harald zur Hausen, Thomas Rothmann, Arnd Hengstermann, Noel J. Whitaker, Martin Scheffner, Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells Journal of Virology. ,vol. 72, pp. 9470- 9478 ,(1998) , 10.1128/JVI.72.12.9470-9478.1998
Terry Hermiston, Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer Journal of Clinical Investigation. ,vol. 105, pp. 1169- 1172 ,(2000) , 10.1172/JCI9973
Jhon D. Minna, Adi F. Gazdar, Translational research comes of age. Nature Medicine. ,vol. 2, pp. 974- 975 ,(1996) , 10.1038/NM0996-974